✦ LIBER ✦

Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-a Monoclonal Antibody Treatment for Crohn's Disease

✍ Scribed by Matsuoka, Katsuyoshi; Kanai, Takanori

Book ID: 120534266
Publisher: S. Karger AG
Year: 2013
Tongue: English
Weight: 97 KB
Volume: 88
Category: Article
ISSN: 0012-2823
DOI: 10.1159/000351386

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Short-Term Study of Chimeric Monoclona

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

✍ Targan, Stephan R.; Hanauer, Stephen B.; van Deventer, Sander J.H.; Mayer, Lloyd 📂 Article 📅 1997 🏛 Massachusetts Medical Society 🌐 English ⚖ 105 KB

Short-term efficacy of chimeric monoclon

Short-term efficacy of chimeric monoclonal antibody cA2 to tumor necrosis factor a for refractory, fistulizing Crohn's disease

✍ Ardizzone, Sandra; Bollani, Simona; Colombo, Elisabetta; Imbesi, Venerina; Bianc 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Serological markers for prediction of re

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease

✍ N Esters; S Vermeire; S Joossens; M Noman; E Louis; J Belaiche; M De Vos; A Van 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 87 KB

Unexpected dramatic clinical response of

Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor (tnfalpha) monoclonal antibody for Crohn’s Disease

✍ Leslie Bank∗; Belinda Hunt 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 24 KB

Efficacy and safety of retreatment with

Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

✍ Paul Rutgeerts; Geert D'Haens; Stephan Targan; Eric Vasiliauskas; Stephen B. Han 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Pharmacodynamic and pharmacokinetic resp

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

✍ Alice B. Gottlieb; Salman Masuda; Rallapalli Ramamurthi; Ahsan Abdulghani; Pat R 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 255 KB